I read the article published by Ünübol et al. 1 with great interest. The authors evaluated mean platelet volume (MPV) and serum lipid profiles in patients with fibromyalgia syndrome (FMS). Mean platelet volume values were higher in patients with FMS than in controls. Although this is a well-written study, it has some methodological drawbacks.
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The researchers screened complete blood counts and biochemical analysis of FMS patients. However, they did not specify the MPV measurement technique in detail. Accurate measurements of platelet count and volume are important for diagnostic, therapeutic, and research purposes. The choice of anticoagulant [ethylenediaminetetraacetic acid (EDTA) or citrate], time interval of measurement, and temperature at which MPV is analyzed are important factors in MPV measurement. The time-dependent swelling of platelets in samples anticoagulated with EDTA can result in an artifactual increase in MPV, causing misinterpretation of prothrombotic changes. 2 In actual daily practice, MPV measurements are performed at room temperature, and temperature factor can be negligible. However, the choice of anticoagulant and time interval of MPV measurement are important issues. Mean platelet volume increases over time in EDTA-anticoagulated samples, and this increase was shown to be proportional with the time delay between sample collection and laboratory analysis. With impedance counting, the MPV increases over time as platelets swell in EDTA, with reported increases of 7.9% within 30 minutes and an overall increase of 13.4% over 24 hours, although the majority of this increase occurs within the first six hours. 2 Dastjerdi et al. 3 recommended measuring MPV within one hour regardless of anticoagulant. Lancé et al. 2 reported that an optimal stability was detected in potassium (K2) EDTA after 120 minutes. It is widely accepted that platelet swelling in test tubes can be minimized by rapid processing of samples, i.e. within less than 1 hour. 3 For a reliable MPV measurement, the potential influence of EDTA anticoagulant on the MPV must be carefully controlled by standardizing the time delay between sampling and analysis. Moreover, the control and standardization of MPV measurement is more challenging in retrospective studies. It would have been beneficial if the authors had indicated these factors.
Mean platelet volume is universally available with routine blood counts by automated hemograms. Compared to smaller platelets, larger platelets have more granules, aggregate more rapidly with collagen, have higher thromboxane A2 level, and express more glycoprotein Ib and IIb/IIIa receptors. 2, 4 On the other hand, MPV can be affected by many risk factors for cardiovascular disease. Thus, all confounding factors should be taken into account, and detailed standardized methods must be used in MPV measurement.
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